Cargando…
Bispecific antibodies in multiple myeloma treatment: A journey in progress
The incorporation of novel agents and monoclonal antibody-based therapies into the treatment of multiple myeloma (MM) has significantly improved long-term patient survival. However, the disease is still largely incurable, with high-risk patients suffering shorter survival times, partly due to weaken...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623099/ https://www.ncbi.nlm.nih.gov/pubmed/36330495 http://dx.doi.org/10.3389/fonc.2022.1032775 |